Immunological Mechanisms in Tuberculosis Vaccine Development

Effective vaccination against tuberculosis hinges on orchestrating both innate and adaptive immune responses to the intracellular pathogen Mycobacterium tuberculosis. Initial recognition by pattern recognition receptors on macrophages and dendritic cells triggers phagocytosis and cytokine secretion, shaping downstream T-cell differentiation. A protective response is dominated by CD4+ Th1 cells producing interferon-γ and tumour necrosis factor-α, which activate infected macrophages, and by Th17 cells that recruit neutrophils and support granuloma integrity. Memory arises from long-lived T-cell subsets and “trained” monocytes bearing epigenetic marks that heighten responsiveness upon re-exposure. Vaccine platforms under investigation include live-attenuated and recombinant mycobacteria, subunit formulations with defined antigens, vector-based constructs and nucleic-acid approaches. Adjuvants targeting Toll-like receptors and other innate sensors enhance antigen presentation and T-cell priming. Optimisation of antigen selection, delivery route and dosing schedule aims to confer durable protection against both primary infection and reactivation of latent disease, addressing a critical unmet need in adult pulmonary tuberculosis.

Research from Nature Portfolio

Recent studies have demonstrated that epigenetic reprogramming of monocytes via trained immunity can be leveraged to augment vaccine efficacy, with selected agonists of nucleotide-binding oligomerisation domain-like receptors promoting sustained histone modifications that bolster macrophage microbicidal activity. Parallel efforts in mRNA vaccine design have shown that lipid-formulated transcripts encoding immunodominant mycobacterial proteins induce robust polyfunctional CD4+ and CD8+ T-cell responses in preclinical models, with a bias towards Th1 and cytotoxic phenotypes. Novel adjuvant systems combining synthetic Toll-like receptor-7/8 ligands with particulate carriers have been found to enhance antigen uptake by dendritic cells and to drive high-avidity T-cell expansion, improving protective efficacy in aerosol challenge experiments. These advances underscore the potential of next-generation platforms to elicit broad, long-lasting immunity against tuberculosis.

Immunological Mechanisms in Tuberculosis Vaccine Development publication trend

The graph below shows the total number of articles in immunological mechanisms in tuberculosis vaccine development across all publications each year (not limited to Nature Index journals).

Technical terms

Th1 cells: CD4+ T lymphocytes that secrete interferon-γ and activate macrophages for intracellular killing.

Th17 cells: CD4+ T lymphocytes producing interleukin-17, crucial for neutrophil recruitment and mucosal defence.

Trained immunity: Epigenetic reprogramming of innate cells leading to enhanced responsiveness upon re-exposure to pathogens.

Antigen-presenting cell (APC): Cell such as a dendritic cell or macrophage that processes and presents antigens to T cells.

Subunit vaccine: Vaccine composed of purified antigens rather than whole organisms, often requiring adjuvants.

Adjuvant: Substance that enhances the magnitude or quality of the immune response to an antigen.

ESAT-6: Early secreted antigenic target 6 kDa, a potent Mycobacterium tuberculosis virulence factor and vaccine antigen.

References

1. The role of ESAT-6 in tuberculosis immunopathology. Frontiers in Immunology (2024).
2. An Overview of the Development of New Vaccines for Tuberculosis. Vaccines (2020).
3. Immunological Characterization of Proteins Expressed by Genes Located in Mycobacterium tuberculosis-Specific Genomic Regions Encoding the ESAT6-like Proteins. Vaccines (2021).